The Carlyle Group - investing through its Asia growth fund - has led a $123 million Series D round for Chinese cancer-focused biotech developer Abbisko Therapeutics.
Sizeable supporting contributions came from Warburg Pincus, OrbiMed, and Lake Bleu Capital, as well as an unspecified US-based investor. Smaller commitments were provided by Janchor Partners, Sage Partners,...
ORI Capital’s 2.8x return on its investment in Kymab was in part based on helping the company make the transition from antibody-based discovery platform to drug development engine
Prosus Ventures, formerly a VC arm of South African media conglomerate Naspers, has led a $30 million Series C round for Indian agricultural technology provider DeHaat.
Having scaled up in fund size to $75 million for its second vintage, Endiya Partners is looking for opportunities in an increasingly attractive yet competitive Indian start-up ecosystem
Placement agent Monument Group has appointed Hiroshi Nishimuro, formerly of Morgan Stanley, as its Japan representative to lead fundraising efforts and manage GP relationships in the country.